Body changes: Antiretroviral therapy and lipodystrophy syndrome in people living with HIV/aids;Alterações corporais: Terapia antirretroviral e síndrome da lipodistrofia em pessoas vivendo com HIV/AIDS

Revista Latino-Americana de Enfermagem

Volumn 20, Issue 5, 2012, Pages 847-853

  Tsuda, Luciana Castelar ^b   da Silva, Mariana Machado ^b   Machado, Alcyone Artioli ^a   Fernandes, Ana Paula Morais ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b WHO Collaborating Centre for Nursing Research Development ^*

Author keywords

Antiretroviral therapy; Highly active; HIV 1; HIV Associated lipodystrophy syndrome; Nursing

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE;

EID: 84870535814     PISSN: 01041169     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-11692012000500005     Document Type: Article

References (26)

1. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS. 1999;13:735-7.
2. Martinez E, Mocroft A, Garcia-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-8.
3. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093-9.
4. Lake JE, Wohl D, Scherzer R, Grunfeld C, Tien PC, Sidney S, et al. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care. 2011;23(8):929-38.
5. Carr A, Cooper DA. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med. 1998;339(18):1296.
6. Shaw AJ, McLean KA, Evans BA. Disorders of fat distribution in HIV infection. Int J STD AIDS. 1998;9(10):595-9.
7. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51-8.
8. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4(3):293-301.
9. Diehl LA, Dias JR, Paes AC, Thomazini MC, Garcia LR, Cinagawa E, et al. Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: relation with metabolic syndrome and cardiovascular risk factors. Arq Bras Endocrinol Metabol. 2008;52(4):658-67.
10. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhre J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60.
11. Blanch J, Rousaud A, Martinez E, De Lazzari E, Milinkovic A, Peri JM, et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis. 2004;38(10):1464-70.
12. Gomes AMT, Silva EMP, Oliveira DC. Representações sociais da AIDS para pessoas que vivem com HIV e suas interfaces cotidianas. Rev. Latino-Am. Enfermagem [Internet]. maio-jun 2011 [acesso 03 set 2012];19(3):[8 telas]. Disponível em: http://www.scielo.br/pdf/rlae/v19n3/pt_06.
13. Sanches RS, Mill J, Machado AA, Donadi EA, Morais Fernandes AP. Facial lipoatrophy: appearances are not deceiving. J Assoc Nurses AIDS Care. 2009;20(3):169-75.
14. Reid C, Courtney M. A randomized clinical trial to evaluate the effect of diet on weight loss and coping of people living with HIV and lipodystrophy. J Clin Nurs. 2007;16(7B):197-206.
15. Chiou PY, Kuo BI, Lee MB, Chen YM, Chuang P, Lin LC. A programme of symptom management for improving quality of life and drug adherence in AIDS/HIV patients. J Adv Nurs. 2006;55(2):169-79.
16. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15(11):1389-98.
17. Castelar L, Silva MM, Castelli EC, Deghaide NH, Mendes-Junior CT, Machado AA, et al. Interleukin-18 and interferon-gamma polymorphisms in Brazilian human immunodeficiency virus-1-infected patients presenting with lipodystrophy syndrome. Tissue Antigens. 2010;76(2):126-30.
18. Cabrero E, Griffa L, Burgos A; HIV Body Physical Changes Study Group. Prevalence and Impact of Body Physical Changes in HIV Patients Treated with Highly Active Antiretroviral Therapy: Results from a Study on Patient and Physician Perceptions. AIDS Patient Care STDS. 2010;24(1):5-13.
19. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42(2):273-80.
20. Han SH, Zhou J, Saghayam S, Vanar S, Phanuphak N, Chen YM, et al. Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocrinol J. 2011;58(6):475-84.
21. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14(10):1309-16.
22. van Vonderen MG, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, Geerlings SE, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One. 2009;4(5):e5647.
23. Gelenske T, Farias FA, Alencar Ximenes RA, Melo HR, Albuquerque MF, Carvalho EH, et al. Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of Pernambuco, Brazil: a case-control study. Metab Syndr Relat Disord. 2010;8(3):271-7.
24. Buffet M, Schwarzinger M, Amellal B, Gourlain K, Bui P, Prévot M, et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol. 2005;33(1):60-4.
25. Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials. 2007;8(5):337-44.
26. Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials. 2008;9(6):407-17.